{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28for+Ruxolitinib%29", "query": { "intervention": "Placebo (for Ruxolitinib)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 19, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28for+Ruxolitinib%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-08T10:44:24.535Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04603495", "title": "Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Myelofibrosis", "Primary Myelofibrosis", "Post-polycythemia Vera Myelofibrosis", "Post-essential Thrombocythemia Myelofibrosis" ], "interventions": [ { "name": "Pelabresib", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 430, "start_date": "2021-04-09", "completion_date": "2027-06-30", "has_results": true, "last_update_posted_date": "2026-07-17", "last_synced_at": "2026-10-08T10:44:24.535Z", "location_count": 20, "location_summary": "Birmingham, Alabama • Chandler, Arizona • La Jolla, California + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04603495" }, { "nct_id": "NCT04921969", "title": "A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Vehicle Cream", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "11 Years", "sex": "ALL", "summary": "2 Years to 11 Years" }, "enrollment_count": 330, "start_date": "2021-07-19", "completion_date": "2024-04-08", "has_results": true, "last_update_posted_date": "2025-03-28", "last_synced_at": "2026-10-08T10:44:24.535Z", "location_count": 64, "location_summary": "Birmingham, Alabama • Hoover, Alabama • Gilbert, Arizona + 49 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Hoover", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04921969" }, { "nct_id": "NCT00952289", "title": "COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "MPN (Myeloproliferative Neoplasms)" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 309, "start_date": "2009-08", "completion_date": "2015-10", "has_results": true, "last_update_posted_date": "2018-03-12", "last_synced_at": "2026-10-08T10:44:24.535Z", "location_count": 88, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Baldwin Park, California + 85 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Baldwin Park", "state": "California" }, { "city": "Bellflower", "state": "California" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00952289" }, { "nct_id": "NCT06673654", "title": "A Study, Comparing Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A, Inc.) to OPZELURA (Ruxolitinib) Cream for the Treatment of Mild-to-Moderate Atopic Dermatitis.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Ruxolitinib Topical Cream 1.5%", "type": "DRUG" }, { "name": "OPZELURA (Ruxolitinib) Cream", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sun Pharmaceutical Industries, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 476, "start_date": "2023-08-11", "completion_date": "2024-09-23", "has_results": false, "last_update_posted_date": "2024-11-05", "last_synced_at": "2026-10-08T10:44:24.535Z", "location_count": 1, "location_summary": "Hawthorne, New York", "locations": [ { "city": "Hawthorne", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06673654" }, { "nct_id": "NCT00820950", "title": "A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "Ruxolitinib phosphate cream", "type": "DRUG" }, { "name": "Dovonex® calcipotriene 0.005%", "type": "DRUG" }, { "name": "Diprolene® AF betamethasone dipropionate 0.05% cream.", "type": "DRUG" }, { "name": "Placebo cream", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 29, "start_date": "2007-05-31", "completion_date": "2009-04-30", "has_results": true, "last_update_posted_date": "2022-02-08", "last_synced_at": "2026-10-08T10:44:24.535Z", "location_count": 6, "location_summary": "Vallejo, California • Boston, Massachusetts • Rochester, New York + 3 more", "locations": [ { "city": "Vallejo", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "New York" }, { "city": "Stony Brook", "state": "New York" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00820950" }, { "nct_id": "NCT07623161", "title": "A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Myelofibrosis", "Anemia" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Elritercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 324, "start_date": "2026-09-10", "completion_date": "2034-03-30", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-08T10:44:24.535Z", "location_count": 30, "location_summary": "Gilbert, Arizona • Glendale, California • Whittier, California + 23 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Glendale", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Coral Springs", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07623161" }, { "nct_id": "NCT02593760", "title": "A Study to Evaluate the Efficacy and Safety of Vismodegib in Combination With Ruxolitinib for the Treatment of Intermediate- or High-Risk Myelofibrosis (MF)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myelofibrosis" ], "interventions": [ { "name": "Placebo", "type": "OTHER" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Vismodegib", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2016-01-25", "completion_date": "2017-07-12", "has_results": false, "last_update_posted_date": "2018-05-11", "last_synced_at": "2026-10-08T10:44:24.535Z", "location_count": 6, "location_summary": "Fort Myers, Florida • St. Petersburg, Florida • West Palm Beach, Florida + 3 more", "locations": [ { "city": "Fort Myers", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02593760" }, { "nct_id": "NCT04551066", "title": "To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Myelofibrosis", "Primary Myelofibrosis", "Post Essential Thrombocythemia Myelofibrosis", "Post Polycythemia Vera Myelofibrosis" ], "interventions": [ { "name": "parsaclisib", "type": "DRUG" }, { "name": "ruxolitinib", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 252, "start_date": "2021-05-24", "completion_date": "2024-11-25", "has_results": true, "last_update_posted_date": "2025-10-21", "last_synced_at": "2026-10-08T10:44:24.535Z", "location_count": 36, "location_summary": "Anchorage, Alaska • Phoenix, Arizona • Berkeley, California + 29 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Berkeley", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04551066" }, { "nct_id": "NCT02119650", "title": "Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "NSCLC (Non-small Cell Lung Carcinoma)" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 76, "start_date": "2014-02-11", "completion_date": "2016-06-21", "has_results": true, "last_update_posted_date": "2018-02-13", "last_synced_at": "2026-10-08T10:44:24.535Z", "location_count": 30, "location_summary": "Phoenix, Arizona • Fayetteville, Arkansas • Fresno, California + 27 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Fresno", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02119650" }, { "nct_id": "NCT01632904", "title": "Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Polycythemia Vera" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Hydroxyurea (HU)", "type": "DRUG" }, { "name": "HU-placebo", "type": "DRUG" }, { "name": "Ruxolitinib-placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 110, "start_date": "2012-06", "completion_date": "2016-05", "has_results": true, "last_update_posted_date": "2017-11-14", "last_synced_at": "2026-10-08T10:44:24.535Z", "location_count": 51, "location_summary": "Scottsdale, Arizona • Fayetteville, Arkansas • Burbank, California + 48 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Burbank", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01632904" } ] }